Co-Authors
This is a "connection" page, showing publications co-authored by Alexandra Schäfer and Ralph Baric.
Connection Strength
4.949
-
Epigenetic Landscape during Coronavirus Infection. Pathogens. 2017 Feb 15; 6(1).
Score: 0.704
-
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021 08 27; 373(6558):991-998.
Score: 0.238
-
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021 03 01; 218(3).
Score: 0.233
-
Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2021 Feb; 590(7844):E22.
Score: 0.232
-
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020 12 18; 370(6523):1464-1468.
Score: 0.228
-
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020 11 12; 183(4):1070-1085.e12.
Score: 0.226
-
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020 10; 586(7830):560-566.
Score: 0.225
-
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020 07 23; 182(2):429-446.e14.
Score: 0.221
-
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
Score: 0.219
-
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
Score: 0.215
-
Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. J Virol. 2018 06 01; 92(11).
Score: 0.192
-
MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018 01 30; 115(5):E1012-E1021.
Score: 0.188
-
Allelic Variation in the Toll-Like Receptor Adaptor Protein Ticam2 Contributes to SARS-Coronavirus Pathogenesis in Mice. G3 (Bethesda). 2017 06 07; 7(6):1653-1663.
Score: 0.180
-
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio. 2015 May 26; 6(3):e00638-15.
Score: 0.156
-
Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio. 2014 May 20; 5(3):e01174-14.
Score: 0.146
-
Systems approaches to Coronavirus pathogenesis. Curr Opin Virol. 2014 Jun; 6:61-9.
Score: 0.146
-
Release of severe acute respiratory syndrome coronavirus nuclear import block enhances host transcription in human lung cells. J Virol. 2013 Apr; 87(7):3885-902.
Score: 0.133
-
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 2021 07 27; 36(4):109450.
Score: 0.060
-
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
Score: 0.060
-
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021 08 05; 184(16):4203-4219.e32.
Score: 0.059
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
Score: 0.059
-
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 03; 591(7850):451-457.
Score: 0.058
-
Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathog. 2021 01; 17(1):e1009287.
Score: 0.058
-
Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1).
Score: 0.058
-
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17; 8(4).
Score: 0.057
-
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020 Dec; 62:103132.
Score: 0.057
-
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2020 11 24; 117(47):29832-29838.
Score: 0.057
-
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020 11 25; 183(5):1367-1382.e17.
Score: 0.057
-
High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell. 2020 10 15; 183(2):429-441.e16.
Score: 0.056
-
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020 10 01; 183(1):169-184.e13.
Score: 0.056
-
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
Score: 0.056
-
Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
Score: 0.056
-
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
Score: 0.056
-
Immune Predictors of Mortality After Ribonucleic Acid Virus Infection. J Infect Dis. 2020 03 02; 221(6):882-889.
Score: 0.054
-
SARS-Like Coronavirus WIV1-CoV Does Not Replicate in Egyptian Fruit Bats (Rousettus aegyptiacus). Viruses. 2018 12 19; 10(12).
Score: 0.050
-
The effect of inhibition of PP1 and TNFa signaling on pathogenesis of SARS coronavirus. BMC Syst Biol. 2016 Sep 23; 10(1):93.
Score: 0.043